Allied Health & Imaging · Independent exam preparation
ABGC Certification Examination: CGC Preparation Guide Study Guide
Practise pedigree calculations, test interpretation, counseling decisions, and ethical care through 60 focused concepts and original ABGC certification study drills.
By CertMedbry · Updated 31 October 2026
Recognize urgent presentations, calculate conditional genetic risks, distinguish screening from diagnosis, and communicate results in ways patients can use. This selective guide connects 60 concepts to decisions across all five ABGC domains. The official content outline remains the full examination scope; use it to identify additional conditions, developmental knowledge, technologies, counseling models, and professional requirements for study.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and credential does this guide address?
The official examination is the American Board of Genetic Counseling (ABGC) Certification Examination. Passing it, together with meeting ABGC's training requirements, leads to the Certified Genetic Counselor (CGC) credential. CGC names the credential rather than a separate examination. ABGC identifies a master's degree from an ACGC-accredited genetic counseling program as the primary qualification to sit for the examination.
How many questions are scored, and how long is the examination?
ABGC specifies 200 multiple-choice questions: 170 scored questions and 30 pretest questions, with four hours allowed. Each question offers four options and requires one best answer.
Certification Process, Exam and Fees · Certified Genetic Counselor (CGC) Candidate Guide
What are the delivery options, and is the examination adaptive?
ABGC currently offers examination delivery at Prometric testing centers in the U.S. and Canada and through remotely proctored testing at a private location. Remote testing requires a computer with a camera and microphone, a stable internet connection, and compliance with Prometric's technical and testing requirements. ABGC describes four-option, single-best-answer multiple-choice items. Its published format information does not specify computer-adaptive delivery. These original drills do not reproduce the examination platform.
Certification Process, Exam and Fees · About the CGC Credential
Which blueprint and effective date apply?
This guide follows the CGC Exam Content Outline effective August 1, 2023, currently linked from ABGC's Program Director Resources page. That effective date identifies the blueprint; it is not a newly issued 2026 syllabus. The linked Candidate Guide's cover is dated April 2023. Use the complete official outline to plan study across all domains and subdomains.
Program Director Resources · Certified Genetic Counselor (CGC) Exam Content Outline · Certified Genetic Counselor (CGC) Candidate Guide
How are the domains weighted?
The outline publishes scored-question counts. Clinical Information, Human Development, and Genetic Conditions has 34 of 170, or 20%; Risk Assessment and Principles of Human Genetics and Genomics has 32, approximately 18.82%; Testing Interpretation, Testing Options, and Reproductive Risk Management has 35, approximately 20.59%; Counseling Skills, Communication, and Education has 30, approximately 17.65%; and Financial/Reimbursement Issues, Resources and Services for Clients, Legal and Regulatory Requirements, and Professional Frameworks has 39, approximately 22.94%. Percentages are calculated from those counts. Concepts are allocated 12, 11, 12, 11, and 14; questions and flashcards each use 4, 4, 4, 3, and 5.
How much preparation should emphasize application and analysis?
The outline specifies 20–25% recall and 75–80% application/analysis. Practise integrating histories, pedigrees, laboratory limitations, patient preferences, and professional obligations. These 20 original questions emphasize applied decisions. Their results identify study needs and do not predict an ABGC passing result.
Does CGC certification establish a license to practise?
ABGC certification demonstrates that its professional standards have been met. Licensure is a separate jurisdictional requirement. ABGC states that many U.S. states require a license; candidates should distinguish certification, institutional credentialing, and applicable practice authorization. This guide's U.S. legal discussions do not describe the law of every state or another country.
About the CGC Credential · Certified Genetic Counselor (CGC) Exam Content Outline
This guide addresses the American Board of Genetic Counseling Certification Examination leading to the Certified Genetic Counselor credential and knowledge needed to enter professional practice. It is independently authored educational material. U.S. legal examples identify their jurisdiction; certification and authorization to practise are separate matters.
Outline used: Certified Genetic Counselor (CGC) Exam Content Outline, effective August 1, 2023; verified as the outline linked from ABGC's current website on 2026-10-13. The workbook label 'Certified Genetic Counselor (CGC)' names the credential awarded through the ABGC Certification Examination, rather than a separate examination. The assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Clinical Information, Human Development, and Genetic Conditions20% (34 of 170; calculated from published counts)
1.When does suspected hyperammonemia require emergency assessment?
The urea cycle removes waste nitrogen; severe dysfunction can allow neurotoxic ammonia to accumulate rapidly. A newborn who initially appears well and then develops poor feeding, lethargy, abnormal breathing, or seizures needs immediate medical assessment. Hyperammonemia is a time-critical physiologic problem even before its genetic cause is established. In counseling triage, acute deterioration changes the task from arranging a routine diagnostic appointment to facilitating emergency evaluation and communicating the suspected metabolic concern.
Apply it
A parent calls about a three-day-old infant who has stopped feeding and is difficult to wake. A sibling died after similar symptoms. Direct the family to immediate emergency assessment and communicate the metabolic concern.
Common pitfall: Waiting for a molecular result or a scheduled genetics visit confuses etiologic confirmation with stabilization; serious neurologic injury can develop while testing remains pending.
2.How does urea cycle treatment address nitrogen accumulation and catabolism?
Treatment must remove excess ammonia and reduce continuing nitrogen release. Nitrogen scavengers such as sodium benzoate and sodium phenylacetate provide alternative nitrogen-excretion pathways; extracorporeal clearance can rapidly remove ammonia in severe cases. Adequate energy delivery helps reverse catabolism, because breakdown of the patient's own protein releases additional nitrogen. Arginine or citrulline supplementation depends on the specific defect; supplementation is not identical across all disorders. Prolonged complete protein restriction can worsen catabolism. Partial deficiencies may first decompensate during illness, fasting, surgery, or the peripartum period.
Apply it
An adult with a partial urea cycle defect becomes confused after surgery and prolonged poor intake. Explain why the metabolic team addresses energy delivery and ammonia removal together rather than relying on dietary protein restriction alone.
Common pitfall: A low-protein instruction is not a complete crisis plan. Treatment must account for the specific defect, severity of hyperammonemia, nutritional needs, and ongoing catabolism.
3.How do cystic fibrosis mechanisms guide treatment?
CFTR dysfunction affects epithelial ion transport, connecting respiratory disease with pancreatic insufficiency, malabsorption, and poor growth. Management addresses different consequences: airway clearance assists secretion removal, antibiotics treat relevant infections, and pancreatic enzyme replacement supports digestion when exocrine pancreatic function is inadequate. CFTR modulators target the protein defect in people with responsive variants; eligibility depends on the variant and applicable treatment criteria. Improvement with a targeted therapy does not automatically eliminate the need for nutritional support, surveillance, or other pulmonary treatment.
Apply it
A child with CF has greasy stools and poor growth despite adequate food intake. Connect possible pancreatic insufficiency to maldigestion and the purpose of prescribed pancreatic enzymes, while separately reviewing pulmonary care.
Common pitfall: One treatment does not address every affected organ. A CF diagnosis alone also does not establish responsiveness to every CFTR modulator.
4.How should an abnormal cystic fibrosis newborn screen and sweat chloride result be interpreted?
An abnormal newborn screen requires diagnostic assessment. The [CFF diagnostic guidelines](https://www.cff.org/medical-professionals/cf-diagnosis-clinical-care-guidelines) recommend bilateral sweat testing when weight exceeds 2 kg and corrected gestational age is at least 36 weeks. Eligible infants should be tested as soon as possible after 10 days of age, ideally within four weeks. Interpretation requires an adequate sweat specimen: below 30 mmol/L makes CF unlikely, 30–59 mmol/L is intermediate, and at least 60 mmol/L supports CF diagnosis in the appropriate screening or clinical context. Intermediate or discordant findings require CF specialist evaluation, repeat sweat testing, and appropriate molecular or functional assessment. One detected CFTR variant alone does not establish recessive CF.
Apply it
An eligible screened infant has one CF-causing variant and sweat chloride of 44 mmol/L. Explain that this intermediate result requires further assessment rather than a definitive affected or carrier label. A premature infant weighing 1.8 kg requires prompt specialist assessment and a plan for adequate sweat testing as eligibility permits; indicated treatment must not await successful collection.
Common pitfall: The four-week goal is qualified by infant eligibility and adequate specimen collection. An insufficient specimen supplies no interpretable chloride result and requires repeat collection. Using 30 mmol/L as the diagnostic threshold confuses intermediate with diagnostic results. A value below 30 mmol/L should not override strong contradictory clinical or molecular evidence, and waiting for symptoms after an abnormal screen can delay care.
5.Which findings satisfy the revised NF1 diagnostic framework?
Without a parent diagnosed with NF1, diagnosis requires at least two criteria: six or more café au lait macules exceeding 5 mm before puberty or 15 mm after puberty; axillary or inguinal freckling; two or more neurofibromas or one plexiform neurofibroma; optic pathway glioma; two or more iris Lisch nodules identified by slit lamp examination or two or more choroidal abnormalities identified by OCT/near-infrared imaging; a characteristic osseous lesion; or a heterozygous pathogenic NF1 variant at approximately 50% variant allele fraction in apparently normal tissue. Osseous examples include sphenoid dysplasia, anterolateral tibial bowing, and long-bone pseudarthrosis. Sphenoid wing dysplasia cannot count separately when an ipsilateral orbital plexiform neurofibroma is present. A child of a parent meeting NF1 criteria needs one criterion from this list. When only café au lait macules and freckling are present, at least one of these pigmentary findings should be bilateral; consider Legius syndrome and other overlapping diagnoses.
Apply it
A prepubertal child without an affected parent has seven bilateral café au lait macules larger than 5 mm but no other criterion. These supply one criterion, so the diagnosis is not yet established. Likewise, an orbital plexiform neurofibroma with ipsilateral sphenoid wing dysplasia does not independently supply two criteria: the associated sphenoid abnormality cannot be counted separately. Another independent criterion is needed in a person without an affected parent.
Common pitfall: Age-dependent manifestations may emerge later, so absent neurofibromas do not exclude early NF1. Clearly segmental pigmentation or neurofibromas raise concern for mosaic NF1 and require assessment under the mosaic framework. Pigmentary findings alone can overlap with Legius syndrome. A tumor-only variant or a VUS does not satisfy the constitutional pathogenic-variant criterion.
GeneReviews: Neurofibromatosis 1 · Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation - PMC
6.How does NF1 surveillance differ from waiting for symptoms?
Surveillance looks for complications before patients necessarily recognize them. NF1 follow-up includes regular clinical examination, childhood ophthalmologic assessment, blood pressure monitoring, and developmental review. Imaging is directed by clinical concerns rather than assuming every asymptomatic patient needs the same scan schedule. The decision principle is to match surveillance to the condition's natural history, age, and existing manifestations. A mildly affected relative does not define the appropriate surveillance needs of another family member.
Apply it
A child with NF1 seems healthy, and the family wants to stop follow-up. Explain why eye assessment, blood pressure checks, and developmental monitoring can remain useful even when no new symptoms are reported.
Common pitfall: Equating surveillance with repeated whole-body imaging misses targeted clinical assessments. A reassuring visit does not permanently remove risks that change with development or age.
7.Which changes in an NF1-associated mass require prompt evaluation?
A known lesion's behavior matters as much as its original label. New persistent pain, rapid growth, or neurologic changes involving a plexiform neurofibroma raise concern for significant complications, including malignant transformation. These findings justify prompt assessment by clinicians experienced in NF1. The counseling role is to recognize the change and facilitate evaluation; symptoms increase concern but do not establish malignancy, which requires an appropriate diagnostic process rather than inference from pain alone.
Apply it
An adult with NF1 reports that a previously stable deep mass has enlarged and now causes persistent pain. Arrange prompt specialist assessment and communicate the change from the individual's previous baseline clearly to the team.
Common pitfall: Calling every neurofibroma harmless can delay evaluation. Calling a painful lesion cancer without diagnostic assessment creates unsupported certainty and may intensify avoidable distress.
8.How should pregnancy dating and developmental windows be aligned with an exposure?
Gestational age conventionally begins with the last menstrual period, approximately two weeks before conception in a typical cycle. Establish the dating convention, agent, dose, and entire exposure interval. The early all-or-none model generally concerns the first two weeks after conception: severe damage may cause loss, while surviving embryos may avoid structural effects, with exceptions. Exposure continuing into organ formation requires assessment of that later interval. Growth and functional maturation remain vulnerable after major structural formation, so a normal anatomy scan cannot exclude every functional effect.
Apply it
A patient began medication at four weeks gestational age and continued for a month. Convert the dates to the same convention as the reference and assess the full interval rather than applying early all-or-none reassurance to every dose.
Common pitfall: A two-week dating error can change the developmental window. Neither survival after an early exposure nor normal anatomy establishes universal absence of exposure-related effects.
9.How should a developmental milestone history distinguish delay from regression?
Record when skills were acquired, whether they remain present, and functioning across gross motor, fine motor, language, social, and adaptive domains. Delay describes acquisition later than expected; regression describes loss of a previously acquired skill. A child can have difficulty in one domain despite stronger performance elsewhere. Standardized developmental screening identifies concerns needing assessment but does not establish their cause. Loss of acquired language or motor abilities changes the clinical question and warrants prompt evaluation rather than routine monitoring of a late milestone alone.
Apply it
A preschool child walks independently and feeds themself but has limited expressive language. Clarify comprehension, hearing, social communication, and the language trajectory. If previously used words have disappeared, document regression explicitly and expedite clinical assessment.
Common pitfall: Normal walking does not establish normal development in every domain. Calling loss of an acquired skill a simple delay can conceal a clinically significant change.
Certified Genetic Counselor (CGC) Exam Content Outline · GeneReviews: Neurofibromatosis 1
10.How should psychological development shape counseling for a child or adolescent?
Assess the young person's actual understanding, emotional concerns, relationships, and participation preferences. Explain a condition in concrete terms suited to their comprehension, then revisit its meaning as school demands, peer relationships, independence, and reproductive questions become relevant. Psychological functioning cannot be inferred from physical severity or chronological age alone. In NF1, attention, learning, social, and emotional difficulties may require assessment even when visible findings are limited. Include the young person's voice while preserving appropriate caregiver support and applicable consent requirements.
Apply it
An adolescent with NF1 avoids school activities because of appearance concerns and asks to speak without a parent present. Explore peer experiences, mood, understanding, and desired support, and arrange an appropriate private discussion within the clinical setting's confidentiality rules.
Common pitfall: Providing the same explanation used in early childhood may miss current concerns. Withdrawal should be explored rather than automatically attributed to ordinary adolescence or to the genetic condition.
GeneReviews: Neurofibromatosis 1 · Communicate Clearly: Tool 4 · Consider Culture: Tool 10
11.How should developmental concerns influence genetic follow-up?
Developmental assessment examines how a child functions across relevant domains and how that pattern changes over time. In conditions such as NF1, learning or behavioral difficulties can require attention even when physical manifestations appear mild. The actionable distinction is between identifying support needs and completing etiologic clarification. A child can receive developmental assessment and educational intervention while diagnostic questions remain open; support should respond to demonstrated needs rather than await a more severe physical phenotype.
Apply it
A school-age child with NF1 has few visible findings but increasing classroom difficulties. Explore learning, attention, and daily functioning, then coordinate developmental or educational assessment rather than judging needs from the number of skin lesions.
Common pitfall: A quiet clinical examination does not measure academic functioning. Attributing every difficulty to a genetic diagnosis can also obscure individual strengths and other contributing factors.
12.Which personal cancer history details change hereditary risk assessment?
Cancer type, age at diagnosis, multiple primary cancers, bilateral disease, and associated noncancer findings help distinguish an inherited predisposition from nonspecific clustering. Accurate diagnoses matter because superficially similar cancer labels can imply different patterns. Integrate personal history with relatives' histories rather than counting affected people alone. An unusually young diagnosis or rare presentation can be informative even in a small family, whereas several common cancers at older ages may have multiple explanations.
Apply it
A patient reports three relatives with cancer but cannot identify the primary sites. Ask about diagnoses and ages, and seek relevant records with permission before treating the family as evidence for a specific hereditary syndrome.
Common pitfall: Counting cancers without verifying their type or timing can inflate risk. A small pedigree or few affected relatives also cannot independently exclude inherited susceptibility.
Risk Assessment and Principles of Human Genetics and Genomics18.82% (32 of 170; calculated from published counts)
13.How does missing family information affect pedigree interpretation?
A pedigree's apparent pattern depends on who is known, their ages, and opportunities to express the condition. Adoption, small family size, early deaths, and incomplete diagnoses reduce the information available. Record uncertainty explicitly rather than coding unknown relatives as unaffected. The practical decision is whether the pedigree truly provides reassuring evidence. A family with few older relatives may reveal little about an adult-onset predisposition even when no additional affected person is reported.
Apply it
An unaffected adult has a young-onset cancer history on one side but knows little about the other side because of adoption. Document the information gap and avoid interpreting that branch as a confirmed negative history.
Common pitfall: Unknown and unaffected are different categories. Treating missing information as absence of disease can make an apparently reassuring pedigree substantially less informative than it appears.
Genetic Testing for Inherited Cancer Risk · Certified Genetic Counselor (CGC) Exam Content Outline
14.How is autosomal dominant transmission separated from clinical outcome?
For a heterozygous parent with a constitutional autosomal dominant variant and an unaffected noncarrier partner, each child has a one-half probability of inheriting that variant. This is a transmission probability, not a prediction of severity or inevitable disease for every condition. Penetrance and expressivity require separate consideration. Previous children's results do not alter the next conception's segregation probability under the same assumptions, so counseling should avoid balancing outcomes across a family.
Apply it
A parent with a dominant variant has two children who did not inherit it. They ask whether the next child must inherit it. Explain that each conception again has a one-half transmission probability under the stated assumptions.
Common pitfall: The expectation that outcomes must balance across siblings is incorrect. A 50% transmission probability also does not mean a child will have half the parent's severity.
What are the different ways a genetic condition can be inherited? · What are reduced penetrance and variable expressivity?
15.Why is an unaffected recessive sibling's carrier probability two-thirds?
When both parents carry pathogenic variants for the same fully penetrant autosomal recessive condition, conception probabilities are one-quarter affected, one-half carrier, and one-quarter noncarrier. Knowing a sibling is unaffected excludes the affected category. Among the remaining three equally likely allele combinations, two are carriers, giving a conditional probability of two-thirds. This calculation requires the unaffected designation to be informative and assumes the standard carrier-parent model rather than a different parental genotype arrangement.
Apply it
An adult's sibling has a fully penetrant childhood recessive condition, and both parents are confirmed carriers. The adult is unaffected and untested. Use two-thirds as the carrier prior before incorporating any new test result.
Common pitfall: Using one-half ignores the known unaffected status. Using two-thirds without checking penetrance, age, and parental genotypes can apply the correct formula to the wrong family.
GeneReviews: Cystic Fibrosis · What are the different ways a genetic condition can be inherited?
16.Which transmission clue distinguishes X-linked inheritance?
In the standard XX/XY model, a father gives his X chromosome to daughters and his Y chromosome to sons. Consequently, paternal transmission of an X-linked variant to a son does not occur through that father's X chromosome. This distinguishes X-linked segregation from autosomal inheritance. Clinical expression in people with two X chromosomes may vary, so the absence of symptoms in a mother does not by itself establish that she lacks the familial variant.
Apply it
A pedigree suggests that a father and son share a disorder. Before concluding that the familial variant is X-linked, verify their diagnoses and molecular findings; the father does not transmit his X chromosome to his son.
Common pitfall: Two affected relatives need not share the same transmission event. Treating every heterozygous person with an X-linked variant as clinically unaffected also oversimplifies expression.
What are the different ways a genetic condition can be inherited?
17.How does mitochondrial inheritance differ from a mitochondrial phenotype?
Maternal inheritance applies to variants in mitochondrial DNA because eggs contribute the embryo's mitochondria. A father does not transmit his mitochondrial DNA variant to his children under this model. However, the label mitochondrial disease describes a biological system, not necessarily the genomic location of the cause. Establish the causal gene and whether it is mitochondrial or nuclear before assigning inheritance; a disease affecting mitochondria can require a different recurrence model.
Apply it
A man with a confirmed mitochondrial DNA variant asks about transmission to his children. Explain the maternal inheritance model, while checking that the laboratory result concerns mitochondrial DNA rather than a nuclear gene affecting mitochondrial function.
Common pitfall: Assigning maternal inheritance from the phrase mitochondrial disease alone confuses organelle function with gene location. A precise molecular diagnosis is needed to select the inheritance model.
What are the different ways a genetic condition can be inherited?
18.What separates reduced penetrance from variable expressivity?
Penetrance concerns whether people carrying a particular variant develop associated features; expressivity concerns how those features differ among affected people. These answer different counseling questions. An unaffected carrier illustrates reduced penetrance, whereas two affected relatives with different severity illustrate variable expressivity. Neither concept changes the underlying segregation probability of a constitutional variant. Keep transmission, the chance of manifestations, and their possible severity separate when explaining what a familial molecular result can predict.
Apply it
Two relatives carry the same dominant variant. One has no associated findings, while the other has substantial disease. Discuss penetrance first; if both were affected but differed in severity, expressivity would describe that difference.
Common pitfall: Using variable expressivity to explain complete absence of manifestations blurs two different concepts. A mild parent's presentation cannot reliably specify an affected child's future severity.
19.How can remaining unaffected change an age-dependent carrier probability?
For an age-dependent condition, remaining unaffected can update a prior carrier probability when age-specific penetrance is known. Multiply each genotype's prior probability by its probability of being unaffected at that age, then normalize across all possibilities. Under a hypothetical model with a one-half carrier prior, 80% penetrance by the current age, and no phenocopies, the updated carrier probability is 0.5×0.2 divided by 0.5×0.2+0.5, or one-sixth.
Apply it
An untested adult initially had a one-half probability of carrying a familial variant. Under the stated 80% age-specific penetrance model, remaining unaffected reduces the probability to one-sixth; explain that this is not a molecular exclusion.
Common pitfall: Multiplying one-half by 20% gives an unnormalized joint probability. Lifetime penetrance also cannot substitute for penetrance at the person's current age in this calculation.
What are reduced penetrance and variable expressivity? · Certified Genetic Counselor (CGC) Exam Content Outline
20.Why can a de novo finding leave a residual sibling risk?
A variant absent from parental blood may have arisen in the child, but parental germline mosaicism remains a possible explanation. Blood samples represent sampled somatic cells and cannot directly exclude a variant confined to some reproductive cells. This separates an apparently de novo result from proof of zero recurrence. In NF1 counseling, assess parental clinical findings and test information while explaining that the affected child's own future transmission risk is a separate question.
Apply it
A child's NF1 variant is absent from both parents' blood, and neither parent has recognized findings. Explain why recurrence for another pregnancy is not necessarily zero and why the child's future reproductive counseling follows a different framework.
Common pitfall: Negative parental blood testing does not sample every germ cell. Giving the parents the affected child's standard dominant transmission probability also answers the wrong recurrence question.
21.How is residual carrier risk calculated after a negative screen?
A negative screen reduces carrier probability according to its detection performance; it does not erase the prior risk. If prior carrier probability is p, carrier detection sensitivity is s, and specificity is assumed to be 100%, the exact posterior is p(1−s)/[1−ps]. The denominator represents everyone expected to test negative. State the assay and population assumptions because a limited panel's sensitivity may not apply equally to every individual or familial variant.
Apply it
For a hypothetical carrier screen, use prior probability 1/25, sensitivity 90%, and specificity 100%. The posterior is 0.004/0.964, or 1/241. Explain the remaining risk using the exact normalized result rather than rounding prematurely.
Common pitfall: Prior risk multiplied by the missed fraction is only the numerator. Omitting normalization produces an approximation that can be materially wrong when prior risk is high.
Certified Genetic Counselor (CGC) Exam Content Outline · GeneReviews: Cystic Fibrosis
22.How do individual carrier probabilities combine into reproductive risk?
For an autosomal recessive condition, multiply the probability that each reproductive partner is a carrier by the one-quarter affected-child probability when both are carriers. This assumes the relevant variants cause the same condition and the carrier probabilities can appropriately be combined as independent. The resulting number is a per-pregnancy disease probability, not either partner's carrier probability. Update the calculation whenever testing or family information changes one of its inputs.
Apply it
One partner is a confirmed carrier; the other's exact residual carrier probability is 1/241. Under the standard recessive model, the affected-child probability is 1×1/241×1/4, or 1/964, for each pregnancy considered independently.
Common pitfall: Multiplying by one-half instead of one-quarter counts transmission from only one carrier. Combining variants in unrelated disease genes does not establish this recessive couple risk.
What are the different ways a genetic condition can be inherited? · GeneReviews: Cystic Fibrosis
23.When is a Hardy–Weinberg estimate appropriate for a learning calculation?
Under a stated two-allele Hardy–Weinberg model, allele frequencies p and q sum to one, and expected genotype frequencies are p², 2pq, and q². For a fully penetrant recessive model, an affected frequency q² allows estimation of q and then carrier frequency 2pq. This is a population model rather than a personalized diagnostic result. Random mating and the model's other assumptions must be considered before transferring its output to a real population.
Apply it
In a hypothetical population satisfying the model, recessive disease frequency is 1/10,000. Then q=0.01, p=0.99, and carrier frequency is 0.0198, approximately 1/50.5. Keep this population estimate distinct from a pedigree-based individual probability.
Common pitfall: Using disease prevalence directly as carrier frequency skips the genotype model. Consanguinity, population structure, and incomplete penetrance can make the simplified assumptions unsuitable for individual counseling.
Certified Genetic Counselor (CGC) Exam Content Outline · Epidemiology | Books | CDC
Testing Interpretation, Testing Options, and Reproductive Risk Management20.59% (35 of 170; calculated from published counts)
24.What distinguishes sensitivity from specificity?
Sensitivity is the proportion of affected individuals who test positive; specificity is the proportion of unaffected individuals who test negative. Their denominators are defined by condition status, not test result. These measures help characterize missed cases and false alarms, but neither directly states the probability that an individual positive result is correct. Before calculating, identify whether the question starts with known disease status or with a laboratory result requiring interpretation.
Apply it
A hypothetical study includes 100 affected and 900 unaffected people. A test detects 90 affected people and correctly excludes 882 unaffected people. Calculate sensitivity as 90/100 and specificity as 882/900, keeping the denominators separate.
Common pitfall: Dividing true positives by all positive results calculates positive predictive value. Confusing these denominators can make a high-performing screen sound more definitive than it is.
Certified Genetic Counselor (CGC) Exam Content Outline · SMFM Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance
25.Why does prevalence change positive predictive value?
Positive predictive value is true positives divided by all positive results. With unchanged sensitivity and specificity, a lower prevalence supplies fewer true positives while the large unaffected population can still contribute false positives. Predictive value therefore depends on the tested population as well as test performance. For counseling, translate hypothetical percentages into expected counts; this exposes why excellent screening performance does not automatically make every positive result a confirmed diagnosis.
Apply it
Among 10,000 hypothetical pregnancies, prevalence is 1%, sensitivity 99%, and specificity 99%. Expect 99 true positives and 99 false positives. The positive predictive value is therefore 50%, despite both performance measures being 99%.
Common pitfall: Substituting sensitivity for predictive value ignores prevalence and false positives. Hypothetical performance figures should not be presented as the measured accuracy of a particular commercial assay.
SMFM Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance
26.How do analytic validity, clinical validity, and utility differ?
Analytic validity concerns whether an assay accurately detects the alteration it claims to measure. Clinical validity concerns how that alteration relates to the clinical condition or risk. Clinical utility concerns whether using the information improves a relevant decision or outcome. These questions form a sequence rather than interchangeable endorsements. A technically reliable result can have uncertain disease meaning, and a meaningful association may still lack evidence that testing helps the particular patient. CLIA laboratory standards do not themselves establish clinical validity or utility.
Apply it
A laboratory accurately measures a DNA change, but its relationship to disease is uncertain and no management consequence is established. Distinguish strong measurement performance from unresolved clinical meaning and benefit when explaining the testing option.
Common pitfall: Laboratory quality certification does not prove medical usefulness. A test's ability to detect many variants also does not establish that reporting them benefits every patient.
How can I be sure a genetic test is valid and useful?: MedlinePlus Genetics · Genetic Testing for Inherited Cancer Risk
27.How should a cancer-risk variant of uncertain significance affect management?
A variant of uncertain significance means available evidence does not establish whether the change increases disease risk. It does not carry the same management implications as a pathogenic result. In hereditary cancer care, decisions should remain grounded in personal and family history and other established risk factors. Explain uncertainty directly and establish a route for updated interpretation because classification may change. Uncertainty about the variant does not make the patient's documented clinical risk disappear.
Apply it
An unaffected patient receives a cancer-panel VUS and asks for preventive surgery solely because of it. Explain why the finding does not justify that decision by itself, while reviewing independent personal and family risk factors.
Common pitfall: Treating uncertain as probably pathogenic converts missing evidence into a positive result. Treating the entire assessment as normal can equally overlook risk supported by history.
28.What makes a negative cancer genetic result informative?
A true negative can be established when a known familial pathogenic variant is specifically absent on appropriate testing. A negative panel in a family without an identified cause may instead be uninformative: the family could have an undetected variant or another explanation for increased risk. The decisive clue is whether there is a validated familial finding against which to interpret the result. Remaining management still considers the person's broader history and risk factors.
Apply it
Two patients have negative results. One was tested for a documented familial pathogenic variant; the other's affected relatives have never been tested. Explain why the first result can resolve a specific inherited risk while the second may not.
Common pitfall: The word negative does not have one universal implication. Even a true negative for one familial variant does not exclude every unrelated cause of cancer.
29.Why is an affected relative often the most informative first person to test?
Testing a relative with a relevant cancer can identify a familial cause that makes subsequent targeted testing interpretable. Beginning with an unaffected relative may yield a negative result without establishing whether the family has a detectable inherited predisposition. Choose the person whose verified phenotype best addresses the clinical hypothesis, while considering availability and consent. Informative-person selection is a reasoning decision; it should not become an absolute rule that blocks all testing when that relative is unavailable.
Apply it
An unaffected adult requests testing after a sister's young-onset cancer. The sister is willing and available. Explain why assessing and testing the affected sister first may clarify the familial question and improve interpretation for other relatives.
Common pitfall: Testing the easiest available relative can sacrifice information. Conversely, an unavailable affected relative does not automatically eliminate the value of carefully counseled testing in someone else.
30.How should tumor findings be distinguished from inherited findings?
Tumor testing examines alterations in cancer cells and can guide treatment. Some detected changes are acquired, while others may also be present constitutionally; the tumor result alone may not distinguish these possibilities. Inherited-risk testing uses an appropriate non-tumor specimen to address germline status. Match the specimen to the clinical question and explain that treatment relevance and family transmission are different implications. A tumor finding can prompt hereditary assessment without proving an inherited condition.
Apply it
A patient's tumor report identifies a cancer-susceptibility gene variant, and a sibling requests predictive testing. First clarify the patient's constitutional status through appropriate assessment rather than treating the tumor finding as a proven familial germline result.
Common pitfall: A variant detected in cancer cells is not automatically inherited. A negative tumor result also does not necessarily answer every separate question about constitutional cancer predisposition.
31.Which method answers a familial balanced-translocation question after a normal microarray?
Chromosomal microarray primarily measures copy number; a balanced translocation can relocate material without a detectable net gain or loss. Conventional chromosome analysis is an appropriate approach to determine whether a known familial balanced translocation is present, guided by the relative's documented karyotype and the rearrangement's visibility. Targeted FISH may supplement analysis when suitable probes can clarify the implicated regions or a subtle arrangement. FISH examines the selected targets rather than providing an unrestricted chromosome survey. Another dosage-only assay would not resolve a copy-neutral arrangement.
Apply it
A patient's parent carries a documented balanced reciprocal translocation. Despite a normal microarray, obtain the familial karyotype and request chromosome analysis designed to assess that arrangement, with targeted FISH if needed for clarification.
Common pitfall: Greater copy-number resolution does not establish chromosome location. Neither a normal microarray nor an unrelated normal FISH result excludes every balanced rearrangement.
32.Why does a positive prenatal cfDNA result require diagnostic counseling?
Prenatal cfDNA screening analyzes placental DNA fragments within maternal blood. Placental and fetal chromosome findings can differ, including through confined placental mosaicism, so a positive result is an increased-risk signal rather than a fetal diagnosis. Provide counseling, ultrasound assessment, and an offer of diagnostic testing. Procedure selection considers the chromosome finding and clinical context because chorionic villus sampling also examines placental tissue, whereas amniocentesis can help address a suspected placental–fetal discrepancy.
Apply it
A positive cfDNA screen is followed by a normal ultrasound. The patient asks whether either result proves the fetal chromosome status. Explain the different information supplied and discuss diagnostic options before any irreversible pregnancy decision.
Common pitfall: A normal ultrasound does not negate a positive screen, and repeating screening does not provide diagnostic confirmation. Placental biology matters when choosing and interpreting follow-up sampling.
SMFM Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance
33.How should a nonreportable prenatal cfDNA result be handled?
A nonreportable result means the assay did not provide an interpretable screening assessment. Low placental DNA contribution and other technical or biological factors can contribute; the result is not equivalent to low risk. SMFM recommends offering genetic counseling, comprehensive ultrasound evaluation, and diagnostic testing because aneuploidy risk can be increased. A repeat screen may be considered through informed decision-making, but its potential delay and possibility of another failure must be addressed explicitly.
Apply it
A patient receives a low-fetal-fraction result near a time-sensitive decision point. Explain that no reassuring risk estimate was produced, offer diagnostic evaluation, and discuss whether repeating screening fits the patient's information needs and timeline.
Common pitfall: Automatically relabeling a failed screen as negative provides false reassurance. Automatically repeating it without discussing diagnostic options can delay the definitive information the patient actually wants.
SMFM Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance
34.How do sequencing, dosage, chromosome, and repeat-expansion methods answer different questions?
Sequence analysis primarily identifies nucleotide substitutions and small insertions or deletions in covered regions. Exon or whole-gene deletions may require validated deletion/duplication analysis; microarray assesses broader genomic dosage. Conventional chromosome analysis evaluates large-scale chromosome organization, including many balanced rearrangements. Repeat-expansion testing requires an assay validated for the relevant repeat and size range; routine sequencing should not be assumed to detect a large expansion. These capabilities can overlap, but performance must be established for the specific alteration class rather than inferred from a test's breadth.
Apply it
When sequencing finds only one CF-causing variant in a patient with convincing CF findings, consider whether deletion/duplication analysis was included. For a known familial balanced translocation or suspected repeat expansion, choose the corresponding structural or repeat-specific assessment.
Common pitfall: A larger gene panel does not automatically supply dosage, structural, or repeat-expansion analysis. A negative result excludes only alterations the assay could reliably detect.
Certified Genetic Counselor (CGC) Exam Content Outline · GeneReviews: Cystic Fibrosis · ACMG Technical Laboratory Standards, Section E
35.How should PGT-M preparation, reproductive alternatives, and prenatal confirmation be discussed?
PGT-M commonly requires variant confirmation, family samples, and individualized assay development before IVF; linked markers can help address errors such as allele dropout. Establish laboratory feasibility before assuming an IVF testing timeline. Discuss conception with or without prenatal diagnosis, IVF with PGT-M, donor gametes, and choosing not to pursue pregnancy according to the family's values. PGT-M remains optional and can have diagnostic errors. ASRM advises offering prenatal testing to confirm its result. A targeted embryo result also leaves unrelated fetal risks unresolved.
Apply it
A couple planning IVF brings a familial variant report. Explain the laboratory preparation and required samples before treatment planning. If pregnancy follows transfer of an embryo reported negative, offer prenatal confirmation and explain its purpose without making it compulsory.
Common pitfall: A diagnostic report is not an immediately available embryo assay. Neither a negative PGT-M result nor acceptance of IVF implies complete fetal genetic health or mandatory prenatal testing.
Counseling Skills, Communication, and Education17.65% (30 of 170; calculated from published counts)
36.How does contracting establish a useful counseling agenda?
Contracting makes the patient's goals, the counselor's role, and the visit's practical scope explicit. Begin by asking what the patient hopes to understand or decide, then negotiate an agenda that also addresses time-sensitive clinical needs. This prevents a technically complete discussion from missing the actual concern. Revisit the agreement when new information changes priorities; the initial agenda organizes collaboration but does not require continuing unchanged when the patient's needs or readiness shift.
Apply it
A referral requests hereditary cancer testing, but the patient mainly fears telling an adult child about family risk. Agree to address communication concerns alongside testing choices, and clarify which decisions need attention during today's visit.
Common pitfall: Assuming the referral question equals the patient's goal can produce an irrelevant visit. Contracting is an ongoing agreement rather than a rigid script or administrative consent form.
Certified Genetic Counselor (CGC) Exam Content Outline · Communicate Clearly: Tool 4
37.How is Rogers's person-centered counseling model applied to genetic decisions?
Rogers's person-centered model emphasizes empathic understanding, unconditional positive regard, and counselor congruence. Empathy seeks the patient's perspective; positive regard preserves respect without making acceptance depend on the patient's choice; congruence requires authentic, professionally appropriate communication. Use open questions, reflection, and summaries to clarify the patient's experience, then focused questions to resolve clinical details. Apply these conditions while providing accurate genetic information and exploring values. The model supports the patient's deliberation rather than using the relationship to secure agreement with the counselor.
Apply it
A patient declines predictive testing despite a management benefit. Reflect their concern about living with the result, explore its meaning without judgment, explain the relevant benefits and limits, and check which option fits their priorities.
Common pitfall: Acceptance does not require endorsing a factual misunderstanding. A person-centered approach still includes clear information, correction of errors, and appropriate clinical recommendations.
Certified Genetic Counselor (CGC) Exam Content Outline · Communicate Clearly: Tool 4 · NSGC Code of Ethics
38.How should emotional distress change results communication?
Emotional distress can reduce a person's ability to absorb information even when their usual health literacy is strong. Acknowledge the expressed emotion, explore its meaning, and prioritize the next useful information rather than completing every technical detail immediately. Assess support, coping, and follow-up needs throughout the encounter. The decision is whether the patient can use additional information now; pacing and a planned return discussion can improve understanding without withholding clinically important facts.
Apply it
After a positive inherited-risk result, a patient repeatedly says they have harmed their children. Pause to explore guilt and what the result means to them, then revisit family implications in manageable portions with follow-up support.
Common pitfall: More facts alone may not resolve distress. Reassuring the patient that there is nothing to worry about can dismiss a real concern and obstruct useful discussion.
Genetic Testing for Inherited Cancer Risk · Communicate Clearly: Tool 4
39.How can family participation support an autonomous decision?
Autonomy includes choosing how trusted relatives participate. Ask the patient whom they want involved, what information may be shared, and whether the proposed decision reflects their preferences. Family involvement becomes problematic when it displaces the patient's voice or introduces coercion. A useful approach distinguishes supportive shared deliberation from pressure, and offers an opportunity for private discussion when needed. Respectful counseling does not assume that every autonomous decision must be made in isolation.
Apply it
A patient wants a partner present for reproductive counseling but becomes silent whenever the partner speaks. Check the patient's preferred involvement and offer private conversation to clarify whether the emerging plan reflects their own wishes.
Common pitfall: Excluding relatives automatically can undermine chosen support. Accepting the most vocal person's answer as the patient's decision can conceal disagreement, pressure, or unexpressed information needs.
40.How is cultural humility applied to an individual counseling encounter?
Cultural humility begins with curiosity about the individual's beliefs and preferences rather than assuming that group membership predicts them. Ask how the patient understands the condition, who participates in decisions, and what practices or values matter to the proposed plan. Explain relevant evidence while exploring how options fit those priorities. The discriminating cue is the person's expressed preference; cultural background may guide respectful questions but should not substitute for asking the patient directly.
Apply it
A counselor expects a patient to decline prenatal diagnosis because of a presumed religious position. Instead, ask what information the patient wants and how their beliefs affect decisions, then discuss options consistent with the answers.
Common pitfall: Using a cultural profile as an individual decision rule stereotypes the patient. Avoiding all discussion of beliefs can also miss factors essential to a workable plan.
41.How does teach-back reveal a misunderstanding?
Teach-back asks the patient to explain important information or the agreed plan in their own words. Frame it as checking the clarity of the explanation, not testing the patient. If the response reveals a misunderstanding, explain differently and check again. Use small information segments rather than waiting until the visit ends. A yes answer to a comprehension question provides little evidence; an accurate explanation of the next action shows whether the communication was usable.
Apply it
After discussing a positive prenatal screen, ask the patient to explain what the result means and what the next test could establish. If they describe screening as a diagnosis, clarify the distinction and repeat teach-back.
Common pitfall: Asking whether everything makes sense is not teach-back. Verbatim repetition may also conceal misunderstanding; the patient should explain the meaning or planned action in their own words.
42.How should a qualified interpreter be integrated into counseling?
Establish preferred spoken and written languages, then arrange qualified language assistance. Address the patient directly, use manageable segments, and allow interpretation before continuing. Qualified interpreters support accuracy, impartiality, and confidentiality, including discussion of emotionally or technically complex results. Language preference should guide the service rather than assumptions about conversational English. Family members can provide support, but their relationship to the patient does not establish the skills or neutrality needed for clinical interpretation.
Apply it
A patient prefers another language for a complex consent discussion. Arrange a qualified interpreter, speak directly to the patient, and confirm understanding through interpreted teach-back rather than asking an accompanying child to translate the information.
Common pitfall: Conversational fluency does not demonstrate comprehension of genetic terminology. A relative's convenience does not outweigh accuracy and privacy, and minor children should not serve as interpreters.
43.How should absolute risk and relative risk be communicated together?
Relative risk describes a proportional comparison, while absolute risk states the actual probability over a defined period. Providing both helps prevent a large relative change from sounding larger than its practical impact. Use consistent denominators and comparable time horizons, and distinguish an estimate from certainty. Natural frequencies can make the calculation concrete. A change from 2 in 100 to 1 in 100 is a 50% relative reduction but a one-percentage-point absolute reduction.
Apply it
A hypothetical intervention lowers ten-year risk from 4 in 100 to 2 in 100. Explain both the 50% relative reduction and the reduction of 2 affected people per 100 over the same period.
Common pitfall: Presenting only the relative reduction can exaggerate perceived benefit. Comparing lifetime risk with a short-term treatment effect also combines incompatible time horizons and obscures the decision.
Assess, Select, and Create Easy-to-Understand Materials: Tool 11 · Communicate Clearly: Tool 4
44.Which features make patient education understandable and actionable?
Useful education states the central message and the next action in familiar language, with visual or written support suited to the person's preferences. Limit unnecessary terminology, define essential terms, and check whether the format is accessible. Reading level alone does not establish usability: a patient must also be able to find the relevant instruction and act on it. Evaluate comprehension through discussion rather than assuming that providing a resource completes education.
Apply it
A patient receives a detailed laboratory report but cannot identify whom to call next. Provide a concise explanation and accessible action plan naming the next service, the reason for contact, and how to arrange follow-up.
Common pitfall: A technically accurate handout can still be unusable. Simplifying vocabulary without clarifying the decision or next action may leave the central practical barrier untouched.
Assess, Select, and Create Easy-to-Understand Materials: Tool 11 · Communicate Clearly: Tool 4
45.What makes genetic testing consent an informed decision?
Informed genetic testing consent requires understanding the purpose, possible results, limitations, alternatives, and relevant implications, together with a voluntary decision. Discuss how positive, negative, and uncertain findings could affect the patient and relatives, including privacy and emotional concerns. Tailor the depth to the test and decision rather than reciting an identical script. The decisive evidence is meaningful understanding and choice; a completed signature documents part of the process but cannot establish comprehension by itself.
Apply it
A patient has signed the laboratory form but believes every result will provide a definite diagnosis. Clarify uncertain and uninformative outcomes, explore whether testing still fits their goals, and check understanding before proceeding with the order.
Common pitfall: A signature cannot correct an inaccurate expectation. Giving exhaustive technical detail without checking understanding also fails to establish that the patient can use the information provided.
Genetic Testing for Inherited Cancer Risk · NSGC Code of Ethics
46.How should counselor self-awareness influence a difficult decision discussion?
Counselor self-awareness means recognizing when personal experiences, values, or emotional reactions may shape framing or recommendations. Identify the patient's goals, present relevant alternatives fairly, and examine whether language is pushing toward the counselor's preferred outcome. Consultation or an appropriate referral can help when personal beliefs interfere with effective care. The distinction is between explaining evidence and directing a preference-sensitive decision through unexamined bias; the patient's informed choice remains the focus.
Apply it
A counselor feels strongly that a patient should choose predictive testing because it helped someone in the counselor's family. Recognize that influence, explore the patient's reasons for declining, and provide balanced information without trying to reproduce that experience.
Common pitfall: Calling a preferred option the responsible choice can introduce pressure. Recognizing bias is useful only if it changes communication or prompts appropriate professional support when needed.
Financial/Reimbursement Issues, Resources and Services for Clients, Legal and Regulatory Requirements, and Professional Frameworks22.94% (39 of 170; calculated from published counts)
47.How should coverage, medical necessity, and patient cost be distinguished?
Clinical appropriateness, payer coverage, and the patient's eventual financial responsibility are related but separate questions. A clinically useful test may still face policy restrictions, and authorization does not necessarily establish that the patient owes nothing. Discuss the proposed service, applicable coverage information, and known uncertainties before testing. The practical decision is whether the patient understands the financial pathway well enough to choose among available options rather than discovering an unexpected barrier after the sample is submitted.
Apply it
A patient hears that testing is covered and assumes the cost is zero. Clarify the distinction between coverage and personal financial responsibility, help obtain an estimate, and discuss whether the available options fit the patient's circumstances.
Common pitfall: Promising no cost from a coverage statement can mislead. A payer's refusal also does not by itself prove that the proposed test lacks clinical value.
Genetic Testing for Inherited Cancer Risk · Certified Genetic Counselor (CGC) Exam Content Outline
48.What makes a medical-necessity letter defensible?
A defensible letter connects verified clinical findings and family history to the proposed test, explains why that method addresses the question, and describes how results could affect care. It should accurately represent the patient's circumstances and the service requested. Match the payer's relevant criteria using existing evidence rather than altering diagnoses to obtain approval. The strongest argument is a clear, truthful clinical rationale whose facts remain consistent with the medical record and actual counseling encounter.
Apply it
A denial requests evidence of early-onset cancer in the family. The record contains only an uncertain age estimate. Clarify the history or obtain records, then submit an accurate explanation rather than choosing an unsupported qualifying age.
Common pitfall: Improving reimbursement by inventing a diagnosis or age undermines professional integrity. A long letter also adds little if it never connects the clinical question to the test.
Certified Genetic Counselor (CGC) Exam Content Outline · NSGC Code of Ethics
49.How should financial assistance be incorporated into a testing plan?
Financial assistance is useful when it addresses the patient's actual barrier and its eligibility, covered services, and application steps are understood. Explore subsidized testing and appropriate support resources before concluding that an uninsured patient has no options. Avoid treating a program's existence as a guarantee of acceptance or comprehensive support. The actionable task is to connect the person to a feasible pathway, identify remaining costs, and preserve informed choice about whether to proceed.
Apply it
An uninsured patient wants hereditary cancer assessment but cannot afford the quoted test. Help identify appropriate subsidized testing resources, clarify eligibility and application steps, and determine whether counseling or follow-up costs remain outside the assistance offered.
Common pitfall: A referral list alone may not overcome cost barriers. Assuming assistance covers every associated service can leave the patient with an unexpected gap in care.
Genetic Testing for Inherited Cancer Risk · Certified Genetic Counselor (CGC) Exam Content Outline
50.Which criteria make a support resource appropriate for a particular client?
Resource selection should consider relevance to the condition and concern, accuracy, accessibility, language, format, and practical usability. A highly regarded website is ineffective if the patient cannot access it or its content does not match the decision. Ask what support the person wants and how they prefer to receive information. Distinguish peer support from individualized medical guidance, and help the patient identify which questions require their clinical team rather than a general discussion group.
Apply it
A newly diagnosed patient wants practical family support but has limited internet access. Offer accessible printed or telephone resources suited to that need, and explain how peer experiences differ from individualized advice about surveillance or treatment.
Common pitfall: Choosing a resource solely because it is popular ignores fit and access. Personal stories can support coping but cannot establish an individual's expected clinical course.
Assess, Select, and Create Easy-to-Understand Materials: Tool 11 · Certified Genetic Counselor (CGC) Exam Content Outline
51.How should time-sensitive resources and referrals be delivered?
Timely resource delivery means matching the referral's urgency to the decision and checking that the patient can actually use the pathway. Identify the next service, its purpose, practical access barriers, and who will follow up. A referral is incomplete when responsibility remains ambiguous or the information arrives after the relevant decision. The key distinction is between providing contact details and facilitating an actionable connection, particularly when language, transportation, cost, or limited time could prevent access.
Apply it
A pregnant patient needs counseling before deciding about diagnostic testing, but the usual referral wait exceeds the decision window. Communicate the time-sensitive need, identify an appropriate available service, and confirm how the patient will connect with it.
Common pitfall: Routine scheduling can be inappropriate for a time-sensitive decision. Labeling a referral urgent without communicating the reason or confirming access may still leave the barrier unresolved.
Certified Genetic Counselor (CGC) Exam Content Outline · Communicate Clearly: Tool 4
52.Which U.S. insurance protections does GINA provide?
The U.S. Genetic Information Nondiscrimination Act provides protections against genetic discrimination in health insurance and covered employment. Its health-insurance protections do not extend to life, disability, or long-term care insurance, although state law may add protection. Explain the type of insurance involved before describing a legal safeguard. GINA also does not guarantee payment for a particular genetic service; protection against discriminatory use of genetic information and a plan's coverage decision are separate issues.
Apply it
An unaffected patient considering predictive testing asks whether GINA protects a future long-term care application. Explain the federal exclusion for that insurance category and distinguish it from health-insurance protections and any additional state-specific provisions.
Common pitfall: Saying all insurance is protected overstates GINA. Saying GINA guarantees test coverage also confuses nondiscrimination protections with reimbursement criteria for a specific clinical service.
53.How do GINA's employment protections depend on context?
GINA's U.S. employment provisions restrict covered employers' use of genetic information in employment decisions. Genetic information includes family medical history, not only the individual's molecular test results. Coverage has boundaries: the law does not apply to employers with fewer than 15 employees, and its employment protections do not apply to the U.S. military. Identify the employer context before making assurances, and distinguish genetic information from other categories of medical information governed by different legal frameworks.
Apply it
A patient assumes avoiding genetic testing prevents any genetic-information issue at work. Explain that family history can itself be genetic information, then clarify whether the employer falls within the relevant federal protections before offering a general assurance.
Common pitfall: Equating genetic information only with laboratory results misses family history. Applying civilian covered-employer protections to every employer or military setting overlooks explicit limits in federal law.
54.How should a request for a completed laboratory report be handled?
In the U.S. HIPAA context described by HHS, patients have a route to direct access to completed laboratory test reports from covered laboratories. Appropriate identity and authorization procedures still apply. Access and interpretation are distinct services: offer counseling to help the patient understand a complex result without treating attendance at counseling as an automatic prerequisite for obtaining the report. The decisive question is whether the report is completed and the request satisfies the applicable access process.
Apply it
A patient requests a completed genetic report before an appointment several weeks away. Follow the applicable access procedure and offer interpretation support rather than withholding the report solely because the counselor has not yet discussed it.
Common pitfall: Concern about misunderstanding does not automatically justify blocking access. A relative's interest in the result also does not establish that they are an authorized recipient.
55.How can family benefit be balanced with confidentiality and data security?
Genetic information can matter to relatives while remaining confidential patient information. Encourage appropriate family communication, clarify what the patient authorizes, and use approved secure channels for identifiable records. Document the result, its interpretation, and the agreed communication plan accurately. Ethical concern for relatives does not create a universal permission to disclose. When obligations conflict, identify the applicable legal and institutional requirements and seek focused consultation rather than improvising an unsupported disclosure rule.
Apply it
A patient's sibling asks the counselor to email the patient's report for reproductive planning. Confirm authorization before sharing and offer the patient a family communication aid or an authorized disclosure pathway that uses an appropriate secure channel.
Common pitfall: Biological relevance does not itself authorize release of another person's record. Removing a name also does not guarantee that detailed familial genetic information is no longer identifiable.
NSGC Code of Ethics · Certified Genetic Counselor (CGC) Exam Content Outline
56.What distinguishes voluntary research consent from routine clinical care?
Research consent requires an understandable explanation of the study and a voluntary decision about participation. Clarify the research purpose, procedures, foreseeable risks and benefits, alternatives, confidentiality provisions, and the distinction between enrollment and necessary clinical care. In applicable U.S. human-subjects research, refusal or withdrawal must not bring a penalty or loss of benefits to which the person is otherwise entitled. Apply the governing regulations and approved protocol. A signature alone does not demonstrate comprehension or voluntariness.
Apply it
A patient signs a study form but believes refusing enrollment would end ordinary genetics care. Pause enrollment, clarify the relationship between research and care, address questions, and assess understanding and voluntariness before any participation decision is finalized.
Common pitfall: A signature cannot cure coercion or therapeutic misconception. A correctable misunderstanding calls for explanation and reassessment rather than automatic enrollment or permanent exclusion.
OHRP Informed Consent FAQs · Federal Register :: Request Access
57.How should a financial conflict of interest affect a test recommendation?
A conflict exists when another interest could influence, or appear to influence, professional judgment. Identify and disclose the relevant relationship, follow institutional and professional management requirements, and ensure that clinical reasoning remains independent. Disclosure alone may be insufficient if the arrangement continues to distort choices. Compare options using the patient's needs, assay capabilities, access, and cost rather than personal benefit. The concern includes perceived conflicts because trust depends on transparent and defensible recommendations.
Apply it
A counselor receives consulting income from a laboratory being considered for testing. Disclose the relationship through the required process, compare suitable alternatives objectively, and apply the institution's conflict-management plan before making or implementing the recommendation.
Common pitfall: Believing oneself unbiased does not remove a perceived conflict. A brief disclosure also does not justify a referral arrangement that compromises independent professional judgment.
58.How should supervision responsibilities match a trainee's competence?
Supervision assigns responsibilities according to the trainee's knowledge, experience, and demonstrated skills. Increase independence deliberately while maintaining access to appropriate guidance and review. A trainee's confidence or program stage is useful context but cannot replace assessment of competence for the specific task. For complex risk calculations or emotionally difficult results, plan the supervisor's involvement in advance. Feedback should develop reasoning and communication while ensuring that patients receive accurate information and appropriate professional support.
Apply it
A trainee has observed results visits but has not independently interpreted mosaic findings. Before assigning a complex disclosure, review their reasoning, agree on supervisory participation, and ensure the discussion is checked rather than relying on their confidence alone.
Common pitfall: Observation alone does not establish readiness for independent practice. Excessive delegation without review and withholding all responsibility regardless of competence both undermine the purpose of supervision.
59.When should a genetic counselor involve another professional?
Professional scope includes recognizing the limits of one's competence and the legal or institutional boundaries of the role. Involve an appropriately qualified professional when a patient's need exceeds those limits, while communicating the genetic information relevant to that consultation. Referral should identify the unresolved clinical question rather than simply transfer responsibility. A counselor can recognize an emergency, support decision-making, and coordinate care without independently undertaking treatment or specialized interpretation beyond their authorized knowledge and role.
Apply it
A patient asks the genetic counselor to select treatment for an acute metabolic crisis. Facilitate immediate medical care, communicate the suspected genetic context, and support the family while the appropriately qualified treatment team manages the crisis.
Common pitfall: Recognizing a condition does not authorize every related treatment decision. Conversely, citing scope should not become a reason to leave an urgent referral or communication need unresolved.
60.How should evidence guide professional and public genetic education?
Evidence-based education distinguishes established findings, plausible interpretation, and unresolved questions. Select sources relevant to the population and decision, consider their date and scope, and avoid presenting an association as proof of benefit. In public communication, accurately represent professional expertise and distinguish personal views from organizational positions. The practical standard is whether the audience can understand what the evidence supports and its limits, rather than whether the message sounds certain or promotes a service.
Apply it
A clinic asks for a public presentation claiming that its broadest panel is best for everyone. Explain differences in clinical indication, uncertain findings, and utility, and revise the claim so the presentation reflects evidence rather than marketing preference.
Common pitfall: A larger panel is not automatically more useful for every patient. Professional authority should not make unsupported claims appear established or imply endorsement by an organization.
NSGC Code of Ethics · Genetic Testing for Inherited Cancer Risk
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Integrate phenotype, diagnostic criteria, natural history, management mechanisms, and urgency before choosing a clinical pathway.
- Distinguish developmental delay, regression, learning needs, and psychological concerns through a worked functional history.
- Write the conditioning information and denominator for every pedigree or residual-risk calculation.
- Separate transmission, penetrance, expressivity, and severity predictions.
- Match the clinical question to the specimen, alteration class, sequencing or cytogenetic method, and assay limitations.
- Practise prenatal screening interpretation, placental–fetal discordance, PGT-M preparation, and prenatal confirmation.
- Apply person-centered counseling, contracting, teach-back, qualified interpretation, and individualized values exploration.
- Give professional, financial, and legal decisions substantial study time: this is the largest domain by published question count.
- Use the complete official outline to extend this selective guide into additional conditions, developmental milestones, technologies, counseling models, and jurisdictional requirements.
A practical preparation plan
1. Map the full outline
Create a study map from every official subdomain. Mark which topics these 60 concepts address and identify the remaining conditions, developmental knowledge, testing technologies, counseling models, and professional requirements that need additional study.
2. Build clinical comparison notes
For each condition studied, connect mechanism, hallmark findings, age-dependent manifestations, diagnostic thresholds, inheritance, surveillance, and treatment. Practise explaining why a cue changes urgency, the differential, or management.
3. Work calculations from first principles
Draw the pedigree, state assumptions, identify the prior, and list the evidence being conditioned on. Recalculate unaffected-sibling probabilities, residual carrier risk, couple risk, and predictive value with normalization and consistent denominators.
4. Interpret results through decisions
For positive, negative, uncertain, mosaic, and nonreportable results, state what was measured, what remains unresolved, and which next step answers the clinical question. Compare sequence, dosage, chromosome, and repeat-expansion capabilities alongside testing purpose.
5. Rehearse counseling and professional cases
Apply a named counseling model to a patient decision, then explain the same result using plain language, an interpreter, and teach-back. Add a family disagreement, cost barrier, privacy request, or conflict of interest and justify an action consistent with the patient's goals and professional obligations.
6. Use the drills diagnostically
Answer the 20 questions before reviewing explanations. For every error, identify the missed cue and explain why each alternative fails. Revisit related flashcards and the relevant outline subdomain; do not interpret a small drill score as a passing prediction.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- About the CGC Credential
- Program Director Resources
- Certified Genetic Counselor (CGC) Exam Content Outline
- Certified Genetic Counselor (CGC) Candidate Guide
- Certification Process, Exam and Fees
- GeneReviews: Urea Cycle Disorders Overview
- GeneReviews: Neurofibromatosis 1
- GeneReviews: Cystic Fibrosis
- Critical Periods of Development
- What are the different ways a genetic condition can be inherited?
- What are reduced penetrance and variable expressivity?
- Genetic Testing for Inherited Cancer Risk
- SMFM Consult Series #74: Cell-free DNA screening for aneuploidies: Updated guidance
- ACMG Technical Laboratory Standards, Section E
- Indications and management of preimplantation genetic testing for monogenic conditions: a committee opinion
- NSGC Code of Ethics
- Use the Teach-Back Method: Tool 5
- Address Language Differences: Tool 9
- Assess, Select, and Create Easy-to-Understand Materials: Tool 11
- Consider Culture: Tool 10
- Communicate Clearly: Tool 4
- Genetic Discrimination
- OHRP Informed Consent FAQs
- HHS Strengthens Patients' Right to Access Lab Test Reports
- How can I be sure a genetic test is valid and useful?: MedlinePlus Genetics
- Federal Register :: Request Access
- Epidemiology | Books | CDC
- Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation - PMC
- Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG) | Genetics in Medicine
- Myotonic dystrophy type 1 testing, 2024 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG) - PMC
- Carl-Rogers-The-Necessary-and-Sufficient-Conditions-of-Therapeutic-Personality-Chang-1-2.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.